TANG Weifang

Source:理学院英文网  Time:2017-12-25  Page Views:102


Professorof MedicinalChemistry

Associate Dean of School of Science

School of Science

Phone: 86-25-86185182

Email: tangwf126@126.com

Research Summary

Professor Tang’s research focuses on Design and synthesis of small molecules as probes of physiologically important cellular processes and as modulators of pathological conditions, with a focus on cardiovascular diseases and cancer. (Organic synthesis; Computer-aided drug design; Chemical biology).The current projects include: Design, synthesis and biological evaluation of pan-Raf/Ret multi-target inhibitors as antitumor drug. Professor Tang is the co-inventor of FN-1501, an anticancer agent in clinical trials.


2008       Ph.D., MedicinalchemistryChinaPharmaceuticalUniversity

2000       M.S., MedicinalchemistryChinaPharmaceuticalUniversity

1988       B.S.,   Chemical pharmacyChinaPharmaceuticalUniversity

Academic Experience

2017-     Professor of MedicinalChemistry, SchoolofScience.

2002-2017Associate Professor of MedicinalChemistry, SchoolofScience.


 [1]Lu Wang, Gaoyuan Zhu, Qing Zhang, Chunqi Duan, Yanmin Zhang, Zhimin Zhang, Yujun Zhou, Tao LU*, Weifang Tang*. Rational design, synthesis, and biological evaluation of Pan-Raf inhibitors to overcome resistance. Organic & Biomolecular Chemistry. 2017,15,3455-3465

[2] Lu Wang, Qing Zhang, Gaoyuan Zhu, Zhimin Zhang, Li Zhang, Tianxiao Mao, Xiang Zhou, Yadong Chen, Tao LU*, Weifang Tang*. Design, synthesis and evaluation of derivatives based on pyrimidies scaffold as potent Pan-Raf inhibitors to overcome resistance. Eur. J. Med. Chem. 2017,130,86-106

[3] Jing Cao, Shuding Dong, Delu Jiang, Peiyu Zhu, Han Zhang, Rui Li, Xuanyu Wang, Weifang Tang* and Ding Du*. β-Functionalization of Indolin-2-one-Derived Aliphatic Acids for the Divergent Synhesis of Spirooxindole γ-Butyrolactones. J. Org. Chem. 2017.82.4186-4193

[4] Yong Zhu, Ting Ran, Xin Chen, Jiaqi Niu, Shuang Zhao, Tao Lu and Weifang Tang*. Synthesis and Biological Evaluation of 1-(2-Aminophenyl)-3-arylurea Derivatives as Potential EphA2 and HDAC Dual Inhibitors. Chem. Pharm. Bull. 2016,64,1136-1141

[5] Weifang Tang and Ding Du. Access to spiro and fused indole derivatives from α,β-unsaturated aldehydes enabled by N-heterocyclic carbene catalysis. Chem. Rec. 2016,16,1489-1500

[6] Yu Jiao, Fei Huang, Pengfei Xu, Yanmin Zhang, Shanfyan, Danfeng Zhang,Tao Lu and Weifang Tang. Discovery and Optimization of 1-(4-chloro-3-(trifluoromethyl) phenyl)-3-(2-amino)pyridine- 3-yl)ureas as Novel KDR Kinase Inhibitors. Med. Chem. 2016,12,328-337

[7] Yu Jiao, Bo-Tao, Yanmin Zhang, Jianbing Wu, Xiaolin Lu, Ying Zheng, Weifang Tang*, Xiang Zhou*. Design, synthesis and evaluation of novel 2-(1H-imidazol- 2-yl)pyridine derivatives as potential BRAF inhibitors and anti-tumor agents. Eur. J. Med. Chem. 2105,90,170-183

[8] Weimin Yang, Yadong Chen, Xiang Zhou, Yazhou Gu, Wenqi Qian, Fan Zhang, Tao Lu*, Weifang Tang* . Design, sythesis and biological evalution of bis-aryl ureas and amides based on 2-amino-3 purinypyridine scaffold as DFG-out B-Raf kinase inhibitors. Eur. J. Med. Chem. 2015,89,581-596
[9] Weimin Yang, Yadong Chen, Yanmin Zhang, Sanzhi Tang ,Hongli Chen, Weifang Tang* and Tao Lu*. Design, Sythesis and Antitumor Activities of Bis- arylureas and Bis-arylamines Based on 1H-benzo[d]imidazole Woiety as Novel B-RafV600E/ VEGFR2 Dual Inhibitors. 
Lett Drug Des Discov. 2014,11, 1079- 1089
[10] Zeng Wu, Ming Yan, Shi-He Hu, Zhi-Cheng Yu, Yong Zhu, Ya-Dong Chen, Hai-Chun Liu, Yan-Min Zhang, Si-Hui Yao, Wei-Fang Tang*, Tao Lu*. Design, sythesis and biological evalution of indole derivatives as novel inhibitors taegeting B-Raf kinase.
Chinese Chemlett. 2014,25,351-354
[11]. Yingyan, Weifang Tang, Yu Zhang, Ding Du, and Taolu. N-Heterocyclic Carbene-Catalyzed Annulations of Enals and Ynals with Indolin-3-ones: Synthesis of 3,4-Dihydropyrano[3,2-b] indol-2-ones.
 Adv. Synth. Catal. 355:321-326, 2013.
[12] Yong Zhu, Xin Chen, Zeng Wu, Yixuan Zheng, Yadong Chen, Weifang Tang*, Tao Lu*. Synthesis and Antitumor Activity of Novel Diaryl Ether Hydroxamic Acids Derivatives as Potential HDAC Inhibitors.
Arch Pharm Res. 2012,35(10): 1723-1732
[13].Botao Xin, Weifang Tang, Yue Wang, Guowu Lin, Haichun Liu, Yu Jiao, Yong Zhu, Haoliang Yuan, Yadong Chen, Yao Lu*. Dessign, sythesis and biological evalution of β-carboline derivatives as novel inhibitors targeting B-Raf kinase.
Bioorg. Med. Chem. Lett. 22(4): 4783-4786, 2012.